Sendai virus, a strong inducer of anti-lentiviral state in ovine cells

De Pablo-Maiso, Lorena ; Echeverría, Irache ; Rius-Rocabert, Sergio ; Luján, Lluis (Universidad de Zaragoza) ; Garcin, Dominique ; De Andrés, Damián ; Nistal-Villán, Estanislao ; Reina, Ramsés

Resumen: Small ruminant lentiviruses (SRLVs) are widely spread in the ovine and caprine populations, causing an incurable disease affecting animal health and production. Vaccine development is hindered owing to the high genetic heterogeneity of lentiviruses and the selection of T-cell and antibody escape mutants, requiring antigen delivery optimization. Sendai virus (SeV) is a respiratory paramyxovirus in mice that has been recognized as a potent inducer of innate immune responses in several species, including mouse and human. The aim of this study was to stimulate an innate antiviral response in ovine cells and evaluate the potential inhibitory effect upon small ruminant lentivirus (SRLV) infections. Ovine alveolar macrophages (AMs), blood-derived macrophages (BDMs), and skin fibroblasts (OSFs) were stimulated through infection with SeV encoding green fluorescent protein (GFP). SeV efficiently infected ovine cells, inducing an antiviral state in AM from SRLV naturally-infected animals, as well as in in vitro SRLV-infected BDM and OSF from non-infected animals. Supernatants from SeV-infected AM induced an antiviral state when transferred to fresh cells challenged with SRLV. Similar to SRLV, infectivity of an HIV-1-GFP lentiviral vector was also restricted in ovine cells infected with SeV. In myeloid cells, an M1-like proinflammatory polarization was observed together with an APOBEC3Z1 induction, among other lentiviral restriction factors. Our observations may boost new approximations in ameliorating the SRLV burden by stimulation of the innate immune response using SeV-based vaccine vectors.

Idioma: Inglés

DOI: 10.3390/vaccines8020206

Año: 2020

Publicado en: Vaccines 8, 2 (2020), 206 [16 pp.]
ISSN: 2076-393X

Factor impacto JCR: 4.422 (2020)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 63 / 140 = 0.45 (2020) - Q2 - T2
Categ. JCR: IMMUNOLOGY rank: 74 / 162 = 0.457 (2020) - Q2 - T2

Factor impacto SCIMAGO: 1.296 - Drug Discovery (Q1) - Immunology (Q1) - Pharmacology (medical) (Q1) - Pharmacology (Q1) - Infectious Diseases (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MICINN/RTI2018-096172-B-C31

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Sanidad Animal (Dpto. Patología Animal)